Candidiasis
📧 Sign up to get email alerts when something new happens for Candidiasis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-22EMA Authorised: Voriconazole Accord (voriconazole) — Accord Healthcare S.L.U.
The EMA authorised Voriconazole Accord (voriconazole) for treatment of fungal infections including Aspergillosis, Candidiasis, and Mycoses, …
-
EMA approval · 2026-07-21EMA Authorised: Vfend (voriconazole) — Pfizer Europe MA EEIG
Pfizer's voriconazole (Vfend) has been authorised by EMA for use in fungal infections including candidiasis, mycoses, and aspergillosis.
-
EMA approval · 2026-07-01EMA Authorised: Noxafil (posaconazole) — Merck Sharp and Dohme B.V
EMA authorises Noxafil (posaconazole) for multiple fungal infections including candidiasis, mycoses, coccidioidomycosis, and aspergillosis.
-
EMA approval · 2026-06-15EMA Authorised: Rezzayo (rezafungin) — Mundipharma GmbH
EMA authorised Rezzayo (rezafungin) for candidiasis and invasive candidiasis, marketed by Mundipharma GmbH.
-
EMA approval · 2026-06-12EMA Authorised: Posaconazole Accord (posaconazole) — Accord Healthcare S.L.U.
Authorised status for Posaconazole Accord, MAH Accord Healthcare S.L.U., in the therapeutic area of mycoses.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-28EMA Authorised: Vfend (voriconazole) — Pfizer Europe MA EEIG
European Medicines Agency authorises Vfend (voriconazole) for fungal infections including candidiasis, mycoses, and aspergillosis.
-
EMA approval · 2026-04-22EMA Authorised: Noxafil (posaconazole) — Merck Sharp and Dohme B.V
The EMA has granted marketing authorization for Noxafil (posaconazole) by Merck Sharp & Dohme B.V. for the treatment and prevention of funga…
-
EMA approval · 2026-04-14EMA Authorised: Vfend (voriconazole) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Vfend (voriconazole) for fungal infections including candidiasis and aspergillosis.
-
EMA approval · 2026-04-08EMA Authorised: Rezzayo (rezafungin) — Mundipharma GmbH
The European Medicines Agency authorized Rezzayo (rezafungin) from Mundipharma GmbH for the treatment of candidiasis, including invasive can…
-
FDA approval · 2026-01-14FDA Approved: FLUCONAZOLE IN SODIUM CHLORIDE — Supplemental Application (Hospira, Inc.)
The FDA approved Hospira's supplemental application for Fluconazole in Sodium Chloride (intravenous formulation), adding this generic IV flu…
-
EMA approval · 2026-01-08EMA Authorised: Cancidas (previously Caspofungin MSD) (caspofungin (as acetate))
EMA has authorised Cancidas (caspofungin acetate) for the treatment of candidiasis and aspergillosis.
-
EMA approval · 2026-01-06EMA Authorised: Voriconazole Hikma (previously Voriconazole Hospira) (voriconazole) — Hikma Farmaceutica (Portugal) S.A.
The EMA authorised Voriconazole Hikma for fungal infections, including aspergillosis and candidiasis, with Hikma Farmaceutica (Portugal) S.A…
-
FDA approval · 2025-11-14FDA Approved: VORICONAZOLE — Original Application (Hainan Poly Pharm. Co., Ltd.)
The FDA approved a generic Voriconazole product from Hainan Poly Pharm. Co., Ltd. via an Original Application (ANDA 220043). It covers voric…
-
EMA approval · 2025-10-21EMA Authorised: Voriconazole Accord (voriconazole) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Voriconazole Accord (voriconazole) for treating aspergillosis, candidiasis and other mycoses; the m…
-
EMA approval · 2025-10-13EMA Authorised: Mycamine (micafungin) — Sandoz Pharmaceuticals d.d.
The EMA authorised Mycamine (micafungin) for candidiasis, with Sandoz Pharmaceuticals d.d. as the marketing authorization holder.
-
EMA approval · 2025-09-09EMA Authorised: Ecalta (anidulafungin) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Ecalta (anidulafungin) for the treatment of candidiasis. Pfizer Europe MA EEIG is the marketing aut…
-
FDA approval · 2025-06-02FDA Approved: AMPHOTERICIN B — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved an original application for Amphotericin B as a generic drug by Heritage Pharmaceuticals (Avet) to treat serious systemic funga…
-
FDA approval · 2025-04-25FDA Approved: FLUCONAZOLE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for fluconazole by Hikma Pharmaceuticals USA Inc., advancing the approval of this generic antifu…
-
FDA approval · 2025-03-21FDA Approved: NYSTATIN — Original Application (Aurobindo Pharma Limited)
FDA approved a generic Nystatin product from Aurobindo Pharma Limited under an Original Application.
-
FDA approval · 2025-03-13FDA Approved: POSACONAZOLE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for posaconazole from Mylan Institutional LLC, updating the approval for the generic product.
-
EMA approval · 2025-01-21EMA Authorised: Posaconazole AHCL (posaconazole) — Accord Healthcare S.L.U.
EMA authorised Posaconazole AHCL by Accord Healthcare S.L.U. for mycoses. The EU marketing authorization was granted on 16 January 2025.
-
FDA approval · 2024-10-24FDA Approved: POSACONAZOLE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s supplemental application for posaconazole (POSACONAZOLE), approving the generic product.
-
FDA approval · 2024-09-16FDA Approved: KETOCONAZOLE — Original Application (ANI Pharmaceuticals, Inc.)
FDA approved ANI Pharmaceuticals' original application for a generic ketoconazole product.
-
FDA approval · 2024-06-25FDA Approved: FLUCONAZOLE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for Fluconazole from Dr. Reddy's Laboratories Limited (ANDA 076658).
-
FDA approval · 2024-05-29FDA Approved: MICAFUNGIN — Original Application (Biocon Pharma Inc.)
FDA approved Biocon Pharma Inc.'s original ANDA for micafungin, a generic antifungal. The approval covers indications including candidiasis …